Supplementary file 1_Risk of hyperglycemia with different statins by type and dose: a network meta-analysis and real-world pharmacovigilance study.docx

The NMA found no statistically significant differences in NODM risk among statins or compared with placebo. However, pravastatin 40 mg/day showed a numerically lower risk estimate (OR: 0.86; 95% CrI: 0.50–1.50), whereas rosuvastatin 20 mg/day and atorvastatin 80 mg/day showed relatively higher estimates. Analyses of intermediate glycemic markers, including FPG and HbA1c, revealed no significant differences across all statin regimens and placebo.

In parallel, FAERS pharmacovigilance analyses identified disproportionate reporting signals for hyperglycemic events with atorvastatin (ROR: 6.11; 95% CI: 5.94–6.29), rosuvastatin (ROR: 2.44; 95% CI: 2.31–2.58), and simvastatin (ROR: 1.22; 95% CI: 1.13–1.32).</p>Conclusion<p>No statistically significant differences in glycemic outcomes were observed among individual statins or compared with placebo. However, numerical variations in point estimates across randomized evidence and pharmacovigilance signals suggest possible differences in glycemic profiles among statins.

Pravastatin showed numerically lower risk estimates; however, these findings were accompanied by substantial uncertainty. Further prospective studies are needed to clarify these observations.</p>